»ý¸í°úÇÐ ºÐ¾ß Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ½ÃÀå ±Ô¸ð´Â 2024³â 79¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2031³â¿¡´Â 768¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2031³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 32.70%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ´Ù±¹Àû ¹× ´ÙÁÖ ÀÓ»ó½ÃÇèÀÇ ±ÞÁõ, ÁÖ¿ä Áö¿ªÀÇ ¸¸¼º ÁúȯÀÇ È®»ê, À¯ÀüÀÚ Ä¡·á ¿¬±¸ µîÀÌ »ý¸í°úÇÐ ºÐ¾ßÀÇ Å¬¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼´Â »ý¸í°úÇÐ ºÐ¾ß Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ¼¼°è ½ÃÀåÀ» Á¾ÇÕÀûÀ¸·Î Æò°¡Çß½À´Ï´Ù. ÁÖ¿ä ºÎ¹®, µ¿Çâ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, °æÀï ȯ°æ, ½ÃÀå¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¿äÀÎ µîÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù.
»ý¸í°úÇÐ ºÐ¾ß Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ¼¼°è ½ÃÀå Á¤ÀÇ
»ý¸í°úÇÐ »ê¾÷Àº ¹æ´ëÇÑ ¾çÀÇ µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ÀÛµ¿ÇÕ´Ï´Ù. µû¶ó¼ µ¥ÀÌÅ͸¦ È¿À²ÀûÀÌ°í ¾ÈÀüÇÏ°Ô ÀúÀåÇÒ ¼ö ÀÖ´Â ¼ö´ÜÀÌ ÇÊ¿äÇÕ´Ï´Ù. µ¥ÀÌÅÍ¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¹æ¹ýÀº Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀ» »ç¿ëÇÏ¿© µ¥ÀÌÅ͸¦ ÀúÀåÇÏ°í ¼ÒÇÁÆ®¿þ¾î¸¦ ½ÇÇàÇÏ´Â °ÍÀÔ´Ï´Ù. À̸¦ ÅëÇØ Àü ¼¼°èÀûÀ¸·Î Áö½ÄÀ» °øÀ¯ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÇÁ·Î¼¼½º°¡ °¡¼ÓÈµÇ¾î ¹é½Å, ÀǾàǰ, ÈÇÐ ¹× »ý¹°ÇÐÀû ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ´õ »¡¸® ¹ßÀü½Ãų ¼ö ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀº ÁÖ¹®Çü µ¥ÀÌÅÍ ÀúÀå ¹× Ã³¸® ´É·ÂÀ» Á¦°øÇÏ´Â ÄÄÇ»ÅÍ ½Ã½ºÅÛ ÀÚ¿øÀÔ´Ï´Ù.
Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀº µ¥ÀÌÅÍ ÀúÀå ¹× Ã³¸® ´É·ÂÀ» ¿Âµð¸Çµå ¹æ½ÄÀ¸·Î Á¦°øÇÏ´Â ÄÄÇ»ÅÍ ½Ã½ºÅÛ ¸®¼Ò½º·Î, ÀÎÅͳÝÀ» ÅëÇØ ¸¹Àº »ç¿ëÀÚ°¡ ¾×¼¼½ºÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅÍ ¼¹ö¸¦ Á¤ÀÇÇÏ´Â µ¥µµ »ç¿ëµË´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ ¸ñÀûÀº ºñ¿ëÀ» Àý°¨ÇÏ°í °í°´ÀÌ IT ¹®Á¦¿¡ ¾ô¸ÅÀÌÁö ¾Ê°í ºñÁî´Ï½º ¸ñÀû¿¡ ÁýÁßÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÔ´Ï´Ù. ¼ºñ½ºÇü ÀÎÇÁ¶ó(IaaS)´Â ÄÄÇ»ÆÃ ¸®¼Ò½º¸¦ Á¦°øÇϴ Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ ¸ðµ¨ÀÔ´Ï´Ù. ¼ºñ½ºÇü ÀÎÇÁ¶ó(IaaS)´Â ¼ºñ½ºÇü ¼ÒÇÁÆ®¿þ¾î(SaaS), ¼ºñ½ºÇü Ç÷§Æû(PaaS)°ú ÇÔ²² ºÐ·ùµË´Ï´Ù. ¼ºñ½ºÇü ÀÎÇÁ¶ó ¸ðµ¨Àº ¿ÂÇÁ·¹¹Ì½º µ¥ÀÌÅͼ¾ÅÍ¿¡¼ ÀÎÇÁ¶ó ±¸¼º¿ä¼Ò¸¦ È£½ºÆÃÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛµ¿ÇÕ´Ï´Ù.
¿ÂÇÁ·¹¹Ì½º µ¥ÀÌÅͼ¾ÅÍ¿¡´Â ½ºÅ丮Áö, ³×Æ®¿öÅ· Çϵå¿þ¾î µîÀÌ Æ÷ÇԵ˴ϴÙ. Çö´ë »çȸÀÇ µðÁöÅÐÈ ÁøÀüÀº »ý¸í°úÇÐ ºÐ¾ßÀÇ Å¬¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ½ÃÀåÀÇ ¼ºÀåÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¹é½Å °³¹ß¿¡´Â 10³âÀÌ °É¸°´Ù°í ÇÕ´Ï´Ù. ±×·¯³ª ¼¼°è Áö½Ä °øÀ¯¿Í Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ µîÀåÀ¸·Î µ¥ÀÌÅÍ À§Ä¡ÀÇ À庮ÀÌ »ç¶óÁö¸é¼ 1³â ¸¸¿¡ ´Þ¼ºÇÒ ¼ö ÀÖ´Â ´Ü°è°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀº ȯÀÚÀÇ ¿ä±¸¿¡ ½Å¼ÓÇÏ°Ô ´ëÀÀÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ȯÀÚ°¡ ´õ ³ªÀº Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï µµ¿ï ¼ö ÀÖ½À´Ï´Ù.
À̸¦ À§ÇØ Å¬¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº Àü ¼¼°è°¡ µ¥ÀÌÅÍ¿¡ Á¢±ÙÇÏ¿© Áö½ÄÀ» È¿À²ÀûÀ¸·Î °øÀ¯Çϰí, ±× °á°ú Èñ±ÍÇÑ »ç·Ê°¡ ´ú °üÂûµÇ´Â °ÍÀ» ¹æÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, Á¶±â °³ÀÔ°ú ¸ÂÃãÇü Ä¡·á¸¦ ÅëÇØ ȯÀÚÀÇ È¸º¹À» °¡¼ÓÈÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¸í°úÇÐ »ê¾÷¿¡¼ Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ ¸¹Àº ÀåÁ¡ Áß Çϳª´Â IT À¯Áöº¸¼ö ¹× Áö¿øÀ» Ŭ¶ó¿ìµå Á¦°ø¾÷ü¿¡ ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á IT ¿î¿µ ºñ¿ëÀ» ÃÖ¼ÒÈÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. À̸¦ ÅëÇØ »ý¸í°úÇÐ »ê¾÷Àº »õ·Î¿î ¹é½Å ¹× ½Å¾à °³¹ß°ú °°Àº Áß¿äÇÑ ¸ñÇ¥¿¡ ÀÚ¿øÀ» ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù.
»ý¸í°úÇÐ ºÐ¾ß Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ¼¼°è ½ÃÀå °³¿ä
´Ù±¹Àû ¹× ´Ù±¹Àû ÀÓ»ó½ÃÇèÀÇ ±ÞÁõ, ÁÖ¿ä Áö¿ª¿¡¼ÀÇ ¸¸¼º ÁúȯÀÇ È®»ê, À¯ÀüÀÚ Ä¡·á ¿¬±¸ µîÀÌ »ý¸í°úÇÐ ¿¬±¸ ºÐ¾ßÀÇ Å¬¶ó¿ìµå ÄÄÇ»ÆÃ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀǾàǰ°ú °°Àº ÀǾàǰ °³¹ßÀÇ Çõ½ÅÀº ȯÀÚ, ÀÇ»ç, ÁöºÒÀÚ¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¿ÜºÎ ¼Ò½º·ÎºÎÅÍÀÇ µ¥ÀÌÅÍ ¼öÁý ¹× ºÐ¼®ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À§Å¹ ¿¬±¸ ±â°ü, Çмú ±â°ü, º´¿ø µî ´Ù¾çÇÑ ÆÄÆ®³Ê°¡ ¼öÇàÇÏ´Â ÀÓ»ó½ÃÇèÀÇ ¼ö°¡ Å©°Ô Áõ°¡Çϰí ÀÖ´Â °Íµµ ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
»ç³» ÀÎÇÁ¶ó µî ±âÁ¸ IT ÀÎÇÁ¶ó¿¡ ºñÇØ ¼ºñ½ºÇü ÀÎÇÁ¶óÀÇ Å¬¶ó¿ìµå ÄÄÇ»ÆÃÀº ½Å·Ú¼ºÀÌ ÈξÀ ´õ ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î »ý¸í°úÇÐ ºÐ¾ßÀÇ Å¬¶ó¿ìµå ÄÄÇ»ÆÃ IaaS ½ÃÀåÀÌ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Ŭ¶ó¿ìµå ±â¹Ý ¸ðµ¨À» ÅëÇØ ¼öÁýµÇ´Â ȯÀÚ µ¥ÀÌÅÍÀÇ º¸¾È¿¡ ´ëÇÑ ½É°¢ÇÑ ¿ì·Á¿Í ´Ù¾çÇÑ »ê¾÷ ºÐ¾ßÀÇ ÇÁ¶óÀ̹ö½Ã ±ÔÁ¦¿¡ ´ëÇÑ ÀûÀýÇÑ ÄÄÇöóÀ̾𽺠ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ ¿ä±¸¿¡ ¸Â°Ô ÄÄÇ»ÆÃ ¼Ö·ç¼ÇÀ» ¸ÂÃãÈÇÏ·Á´Â ¿òÁ÷ÀÓ°ú Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ¿¡¼ ¼Ò¼È ¹Ìµð¾îÀÇ ºÎ»óÀ¸·Î ÀÎÇØ Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ äÅ÷üÀÌ °¡¼Ó鵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±¹°¡¿¡¼ ¸¸¼º ÁúȯÀÌ ¸¸¿¬ÇÔ¿¡ µû¶ó ±â¾÷µéÀº »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå Âü¿©Àڵ鿡°Ô Èï¹Ì·Î¿î ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
Cloud Computing IaaS In Life Science Market size was valued at USD 7.99 Billion in 2024 and is projected to reach USD 76.86 Billion by 2031, growing at a CAGR of 32.70% during the forecast period 2024-2031. A surge in multinational and multistate clinical trials, widespread incidence of chronic diseases in major regions, and gene therapy research are driving the market for cloud computing IaaS in life science. The Global Cloud Computing IaaS In Life Science Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Cloud Computing IaaS In Life Science Market Definition
The life science industry functions on large volumes of data. As a result, it requires an efficient and secure means of storing the data. An effective way of making the data more accessible is by using cloud-based platforms for storing data and executing software. This allows processes to be accelerated because of the global knowledge-sharing created, which results in the faster rollout of vaccines, medicines, and an understanding of chemical and biological systems. Cloud computing is a computer system resource that provides data storage and processing capacity on demand.
It's also used to define data servers that are accessible over the internet to a large range of users. The goal of cloud computing is to save expenses and allow customers to focus on their business objectives rather than being blocked by IT problems. Infrastructure as a service, or IaaS, is a cloud computing model that provides computing resources. Infrastructure as a service (IaaS) is categorized along with software as a service (SaaS) and platform as a service (PaaS). The infrastructure as a service model works by hosting the infrastructure components in an on-premise data center.
The on-premise data center includes storage, networking hardware, and more. The increasing digitalization in today's society is leading to the growth of Cloud Computing IaaS In Life Science Market. Vaccine development might take up to ten years. However, owing to the advent of global knowledge sharing and cloud computing, that procedure may now be accomplished in a year by eliminating the barriers related to data location. Furthermore, cloud computing can help patients receive better treatment by allowing for a faster response to their needs.
This is accomplished by efficiently knowledge sharing by having a cloud-based platform to access data globally, which results in fewer rare cases being observed. As a result, patient recovery increases because of earlier intervention and customized treatment. One of the many benefits of cloud computing in the life science industry is the ability to minimize IT operational costs by outsourcing IT maintenance and support to the cloud provider. This allows the life science industry to reallocate resources towards key objectives such as developing new vaccines or medicines.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Global Cloud Computing IaaS In Life Science Market Overview
A surge in multinational and multistate clinical trials, widespread incidence of chronic diseases in major regions, and gene therapy research are driving the market for cloud computing in life sciences R&D. Drug development innovations, such as personalized medicines, necessitate the data collection and analysis from a wide range of external sources, including patients, physicians, and payers. The demand for cloud computing solutions is increasing as a result of this factor. Furthermore, the market is expected to benefit from a significant number of clinical trials conducted by various partners such as contract research organizations, academic institutions, and hospitals.
In comparison to traditional IT infrastructures, such as in-house infrastructure, cloud computing in infrastructure as a service is also much more reliable. These reasons are propelling the Cloud Computing IaaS In Life Science Market. However, significant security concerns of patient data obtained through cloud-based models, as well as a lack of proper compliance with various industry privacy regulations, have restrained the market's growth. Furthermore, the growing customization of computing solutions to meet specific needs and the rise of social media in cloud computing is expected to accelerate the adoption rate. In addition, the widespread incidence of chronic diseases in many countries has prompted companies to invest heavily in R&D to develop targeted and new therapies, opening exciting opportunities for market players.
The Global Cloud Computing IaaS In Life Science Market is Segmented on the basis of Component, Application, Deployment Model, And Geography.
Based on Component, The market is segmented into Software, Hardware, and Services. Hardware as a Service is another name for IaaS. (HaaS). It's one of the cloud computing platform's layers. Customers can outsource their IT infrastructures, such as servers, networking, processing, storage, virtual machines, and other resources, to the business. Customers access these resources on the Internet using a pay-as-per-use model.
Based on Application, The market is segmented into Nonclinical Information Systems (NCIS) and Clinical Information Systems. A non-clinical information system, often known as a hospital information system, is a computer system that manages, stores, and rechecks all medical information in hospitals, such as patient health history, prescriptions, and other special comments, all of which is stored electronically. Non-clinical systems aid decision-making and improve the efficiency and effectiveness of clinical care delivery, reducing paperwork.
Based on Deployment Model, The market is segmented into Private Cloud, Public Cloud, and Hybrid Cloud. A private cloud (also known as an internal cloud or corporate cloud) is a cloud computing environment in which all hardware and software resources are dedicated to a single customer and only that customer has access to them. Private cloud combines the elasticity, scalability, and ease of service delivery of cloud computing with the access control, security, and resource customization of on-premises infrastructure.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.